Rezultati pretrage - Ken Lebioda

Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and modera... od Peter P. Toth, Gregory G. Schwartz, Stephen J. Nicholls, Aziz Khan, Michael Szarek, Henry N. Ginsberg, Jan O. Johansson, Kamyar Kalantar-Zadeh, Ewelina Kulikowski, Ken Lebioda, Norman C.W. Wong, Michael Sweeney, Kausik K. Ray

Connect to this object online.